Citations (114)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Nurbubu T. Moldogazieva, Sergey P. Zavadskiy, Susanna S. Sologova, Innokenty M. Mokhosoev & Alexander A. Terentiev. (2021) Predictive biomarkers for systemic therapy of hepatocellular carcinoma. Expert Review of Molecular Diagnostics 21:11, pages 1147-1164.
Read now
Read now
Yuan Liu, Lamei Chen, Huabing Yuan, Shenghong Guo & Gang Wu. (2020) LncRNA DANCR Promotes Sorafenib Resistance via Activation of IL-6/STAT3 Signaling in Hepatocellular Carcinoma Cells. OncoTargets and Therapy 13, pages 1145-1157.
Read now
Read now
Ahmed W Moawad, Janio Szklaruk, Chandana Lall, Katherine J Blair, Ahmed O Kaseb, Amita Kamath, Scott A Rohren & Khaled M Elsayes. (2020) Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging. Journal of Hepatocellular Carcinoma 7, pages 77-89.
Read now
Read now
Xie Weng, Lixian Zeng, Feifei Yan, Mengxue He, Xiuqiong Wu & Dayong Zheng. (2019) Cyclin-dependent kinase inhibitor 2B gene is associated with the sensitivity of hepatoma cells to Sorafenib. OncoTargets and Therapy 12, pages 5025-5036.
Read now
Read now
Chi-Chun Huang, Hsin-Yi Chen, Ruei-Hsin Chang, Pen-An Liao, Heng-Hui Lien, Chih-Sheng Hung, Sien-Sing Yang & Jui-Ting Hu. (2019) A real-life experience of sorafenib treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis at Cathay General Hospital, 2007–2015. Drug Design, Development and Therapy 13, pages 397-404.
Read now
Read now
Simone Jueliger, John Lyons, Sara Cannito, Illar Pata, Pille Pata, Marianna Shkolnaya, Oriana Lo Re, Marion Peyrou, Francesc Villarroya, Valerio Pazienza, Francesca Rappa, Francesco Cappello, Mohammad Azab, Pietro Taverna & Manlio Vinciguerra. (2016) Efficacy and epigenetic interactions of novel DNA hypomethylating agent guadecitabine (SGI-110) in preclinical models of hepatocellular carcinoma. Epigenetics 11:10, pages 709-720.
Read now
Read now
Mirjana Urosevic-Maiwald, Marjam J Barysch, Phil F Cheng, Maria B Karpova, Hans Steinert, Michal J Okoniewski & Reinhard Dummer. (2015) In vivo profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. OncoImmunology 4:2.
Read now
Read now
Elisa Carra, Federica Barbieri, Daniela Marubbi, Alessandra Pattarozzi, Roberto E. Favoni, Tullio Florio & Antonio Daga. (2013) Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures. Cell Cycle 12:3, pages 491-500.
Read now
Read now
Articles from other publishers (106)
Kimia Karimi, Sarah Mojtabavi, Pooya M. Tehrany, Melina Maghsodlou Nejad, Aryan Rezaee, Shahab Mohtashamian, Erfan Hamedi, Farnaz Yousefi, Farshid Salmani, Mohammad Arad Zandieh, Noushin Nabavi, Navid Rabiee, Yavuz Nuri Ertas, Shokooh Salimimoghadam, Mohsen Rashidi, Parham Rahmanian, Kiavash Hushmandi & Wei Yu. (2023) Chitosan-based nanoscale delivery systems in hepatocellular carcinoma: Versatile bio-platform with theranostic application. International Journal of Biological Macromolecules 242, pages 124935.
Crossref
Crossref
Riccardo Nevola, Augusto Delle Femine, Valerio Rosato, Loreta Anesti Kondili, Maria Alfano, Davide Mastrocinque, Simona Imbriani, Pasquale Perillo, Domenico Beccia, Angela Villani, Rachele Ruocco, Livio Criscuolo, Marco La Montagna, Antonio Russo, Aldo Marrone, Ferdinando Carlo Sasso, Raffaele Marfella, Luca Rinaldi, Nicolino Esposito, Giuseppe Barberis & Ernesto Claar. (2023) Neoadjuvant and Adjuvant Systemic Therapies in Loco-Regional Treatments for Hepatocellular Carcinoma: Are We at the Dawn of a New Era?. Cancers 15:11, pages 2950.
Crossref
Crossref
Pennapha Suknoppakit, Apirath Wangteeraprasert, Orakot Simanurak, Julintorn Somran, Supawadee Parhira, Dumrongsak Pekthong & Piyarat Srisawang. (2023) Calotropis gigantea stem bark extract activates HepG2 cell apoptosis through ROS and its effect on cytochrome P450. Heliyon 9:5, pages e16375.
Crossref
Crossref
Khurram Shahzad, Mohammad Asad, Abdullah M. Asiri, Muhammad Irfan & Muhammad Adnan Iqbal. (2023)
In-vitro
anticancer profile of recent ruthenium complexes against liver cancer
. Reviews in Inorganic Chemistry 43:1, pages 33-47.
Crossref
Crossref
Katja Kološa, Bojana Žegura, Martina Štampar, Metka Filipič & Matjaž Novak. (2023) Adverse Toxic Effects of Tyrosine Kinase Inhibitors on Non-Target Zebrafish Liver (ZFL) Cells. International Journal of Molecular Sciences 24:4, pages 3894.
Crossref
Crossref
Noor-ul-Huda Butt & Sultan Nacak Baytas. (2023) Advancements in Hepatocellular Carcinoma: Potential Preclinical Drugs and their Future. Current Pharmaceutical Design 29:1, pages 2-14.
Crossref
Crossref
Yan-Ting Chen, Ainun Nizar Masbuchin, Yi-Hsien Fang, Ling-Wei Hsu, Sheng-Nan Wu, Chia-Jui Yen, Yen-Wen Liu, Yu-Wei Hsiao, Ju-Ming Wang, Mohammad Saifur Rohman & Ping-Yen Liu. (2023) Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways. Biomedicine & Pharmacotherapy 157, pages 113962.
Crossref
Crossref
Deniz Tümen, Philipp Heumann, Karsten Gülow, Cagla-Nur Demirci, Lidia-Sabina Cosma, Martina Müller & Arne Kandulski. (2022) Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma. Biomedicines 10:12, pages 3202.
Crossref
Crossref
Longhao Wang, Tao Hu, Zhibo Shen, Yuanyuan Zheng, Qishun Geng, Lifeng Li, Beibei Sha, Miaomiao Li, Yaxin Sun, Yongjun Guo, Wenhua Xue, Dan Xuan, Ping Chen & Jie Zhao. (2022) Inhibition of USP1 activates ER stress through Ubi-protein aggregation to induce autophagy and apoptosis in HCC. Cell Death & Disease 13:11.
Crossref
Crossref
Mohammed Esawie, Manal L. Louka, Amany H. Hasanin, Amal A. El-Kholy & Hebatalla Said Ali. (2022) High-glucose-induced hyperosmolar stress sensitizes HepG2 cell lines to sorafenib. Gene 844, pages 146828.
Crossref
Crossref
Suzan Abdu, Nouf Juaid, Amr Amin, Mohamed Moulay & Nabil Miled. (2022) Therapeutic Effects of Crocin Alone or in Combination with Sorafenib against Hepatocellular Carcinoma: In Vivo & In Vitro Insights. Antioxidants 11:9, pages 1645.
Crossref
Crossref
Utibe-Abasi S. Udoh, Moumita Banerjee, Pradeep K. Rajan, Juan D. Sanabria, Gary Smith, Mathew Schade, Jacqueline A. Sanabria, Yuto Nakafuku, Komal Sodhi, Sandrine V. Pierre, Joseph I. Shapiro & Juan R. Sanabria. (2022) Tumor-Suppressor Role of the α1-Na/K-ATPase Signalosome in NASH Related Hepatocellular Carcinoma. International Journal of Molecular Sciences 23:13, pages 7359.
Crossref
Crossref
Siyu Li, Wenhan Pei, Wei Yuan, Dan Yu, Huanjie Song & Hui Zhang. (2022) Multi-omics joint analysis reveals the mechanism of action of the traditional Chinese medicine Marsdenia tenacissima (Roxb.) Moon in the treatment of hepatocellular carcinoma. Journal of Ethnopharmacology 293, pages 115285.
Crossref
Crossref
Michele Manganelli, Ilaria Grossi, Jessica Corsi, Vito Giuseppe D’Agostino, Katarina Jurikova, Emilio Cusanelli, Sarah Molfino, Nazario Portolani, Alessandro Salvi & Giuseppina De Petro. (2022) Expression of Cellular and Extracellular TERRA, TERC and TERT in Hepatocellular Carcinoma. International Journal of Molecular Sciences 23:11, pages 6183.
Crossref
Crossref
Xianbo Wu, Yihua Xu, Qi Liang, Xinwei Yang, Jianli Huang, Jie Wang, Hong Zhang & Jianyou Shi. (2022) Recent Advances in Dual PI3K/mTOR Inhibitors for Tumour Treatment. Frontiers in Pharmacology 13.
Crossref
Crossref
John S. Wang, Omar Elghawy, Brett R. Kurpiel & Michael G. Douvas. (2022) Diagnosis and Management of Atypical Chronic Myeloid Leukemia with a t(2;13)(q33;q12) Translocation. Case Reports in Hematology 2022, pages 1-5.
Crossref
Crossref
Laura Contreras, Alfonso Rodríguez-Gil, Jordi Muntané & Jesús de la Cruz. (2022) Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. Cancers 14:5, pages 1204.
Crossref
Crossref
Homood M. As Sobeai, Munirah Alohaydib, Ali R. Alhoshani, Khalid Alhazzani, Mashal M. Almutairi, Tareq Saleh, David A. Gewirtz & Moureq R. Alotiabi. (2022) Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells. Saudi Pharmaceutical Journal 30:1, pages 91-101.
Crossref
Crossref
Anil Kumar Moola, S. Geetha Renuka, Harish Kumar Seenivasan, Nivethitha Manickam, Sujatha Peela & B.D. Ranjitha Kumari. 2022. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3. Theranostics and Precision Medicine for the Management of Hepatocellular Carcinoma, Volume 3
81
92
.
Saleh A Alqahtani & Massimo G Colombo. (2021) Current status of first-line therapy, anti-angiogenic therapy and its combinations of other agents for unresectable hepatocellular carcinoma. World Journal of Gastrointestinal Oncology 13:12, pages 2038-2049.
Crossref
Crossref
Ghada H. Mansour, Mohammed A. El-Magd, Dalia H. Mahfouz, Ismail A. Abdelhamid, Magda F. Mohamed, Nada S. Ibrahim, Abdel Hady A. Abdel Wahab & Emad M. Elzayat. (2021) Bee venom and its active component Melittin synergistically potentiate the anticancer effect of Sorafenib against HepG2 cells. Bioorganic Chemistry 116, pages 105329.
Crossref
Crossref
Xili Jiang, Wei Zhang, Lifeng Li & Shucai Xie. (2021) Integrated Transcriptomic Analysis Revealed Hub Genes and Pathways Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Pathology and Oncology Research 27.
Crossref
Crossref
Adam Bieniek, Marek Wiśniewski, Joanna Czarnecka, Jędrzej Wierzbicki, Marcin Ziętek, Maciej Nowacki, Dariusz Grzanka, Tomasz Kloskowski & Katarzyna Roszek. (2021) Porphyrin Based 2D-MOF Structures as Dual-Kinetic Sorafenib Nanocarriers for Hepatoma Treatment. International Journal of Molecular Sciences 22:20, pages 11161.
Crossref
Crossref
Giuseppa Augello, Maria Rita Emma, Antonina Azzolina, Roberto Puleio, Lucia Condorelli, Antonella Cusimano, Lydia Giannitrapani, James A. McCubrey, Juan Lucio Iovanna & Melchiorre Cervello. (2021) The NUPR1/p73 axis contributes to sorafenib resistance in hepatocellular carcinoma. Cancer Letters 519, pages 250-262.
Crossref
Crossref
Zając A, Sumorek-Wiadro J, Maciejczyk A, Langner E, Wertel I, Rzeski W & Jakubowicz-Gil J. (2021) LY294002 and sorafenib as inhibitors of intracellular survival pathways in the elimination of human glioma cells by programmed cell death. Cell and Tissue Research 386:1, pages 17-28.
Crossref
Crossref
Qingli Li & Tianqiang Song. (2021) Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. Frontiers in Oncology 11.
Crossref
Crossref
Davide Gnocchi, Francesca Castellaneta, Gianluigi Cesari, Giorgio Fiore, Carlo Sabbà & Antonio Mazzocca. (2021)
Treatment of liver cancer cells with ethyl acetate extract of
Crithmum maritimum
permits reducing sorafenib dose and toxicity maintaining its efficacy
. Journal of Pharmacy and Pharmacology 73:10, pages 1369-1376.
Crossref
Crossref
Jianming Wei, Bo Wang, Xibo Gao & Daqing Sun. (2021) Prognostic Value of a Novel Signature With Nine Hepatitis C Virus-Induced Genes in Hepatic Cancer by Mining GEO and TCGA Databases. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Michele Manganelli, Ilaria Grossi, Manuela Ferracin, Paola Guerriero, Massimo Negrini, Michele Ghidini, Chiara Senti, Margherita Ratti, Claudio Pizzo, Rodolfo Passalacqua, Sarah Molfino, Gianluca Baiocchi, Nazario Portolani, Eleonora Marchina, Giuseppina De Petro & Alessandro Salvi. (2021) Longitudinal Circulating Levels of miR-23b-3p, miR-126-3p and lncRNA GAS5 in HCC Patients Treated with Sorafenib. Biomedicines 9:7, pages 813.
Crossref
Crossref
Sarinya Palakhachane, Yuwaporn Ketkaew, Natthaya Chuaypen, Jitnapa Sirirak, Jutatip Boonsombat, Somsak Ruchirawat, Pisit Tangkijvanich, Apichart Suksamrarn & Panupun Limpachayaporn. (2021) Synthesis of sorafenib analogues incorporating a 1,2,3-triazole ring and cytotoxicity towards hepatocellular carcinoma cell lines. Bioorganic Chemistry 112, pages 104831.
Crossref
Crossref
Antonella Cammarota, Antonio D’Alessio, Tiziana Pressiani, Lorenza Rimassa & Nicola Personeni. (2021) Systemic Treatment for Older Patients with Unresectable Hepatocellular Carcinoma. Drugs & Aging 38:7, pages 579-591.
Crossref
Crossref
Chanhee Park, Jiwon Oh, Won Mo Lee, Hye Ran Koh, Uy Dong Sohn, Seung Wook Ham & Kyungsoo Oh. (2021) Inhibition of NUPR1–Karyopherin β1 Binding Increases Anticancer Drug Sensitivity. International Journal of Molecular Sciences 22:6, pages 2794.
Crossref
Crossref
Mahmoud A. Younis, Ikramy A. Khalil, Yaser H.A. Elewa, Yasuhiro Kon & Hideyoshi Harashima. (2021) Ultra-small lipid nanoparticles encapsulating sorafenib and midkine-siRNA selectively-eradicate sorafenib-resistant hepatocellular carcinoma in vivo. Journal of Controlled Release 331, pages 335-349.
Crossref
Crossref
Umme Ruman, Kalaivani Buskaran, Giorgia Pastorin, Mas Jaffri Masarudin, Sharida Fakurazi & Mohd Zobir Hussein. (2021) Synthesis and Characterization of Chitosan-Based Nanodelivery Systems to Enhance the Anticancer Effect of Sorafenib Drug in Hepatocellular Carcinoma and Colorectal Adenocarcinoma Cells. Nanomaterials 11:2, pages 497.
Crossref
Crossref
Asbiel Hasbum, Jaqueline Quintanilla, Juan A Amieva Jr, May-Hui Ding, Arkene Levy & Sue Anne Chew. (2021) Strategies to better treat glioblastoma: antiangiogenic agents and endothelial cell targeting agents. Future Medicinal Chemistry 13:4, pages 393-418.
Crossref
Crossref
Michela Anna Polidoro, Joanna Mikulak, Valentina Cazzetta, Ana Lleo, Domenico Mavilio, Guido Torzilli & Matteo Donadon. (2020) Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World Journal of Gastroenterology 26:33, pages 4900-4918.
Crossref
Crossref
Mina S. Makary, Umang Khandpur, Jordan M. Cloyd, Khalid Mumtaz & Joshua D. Dowell. (2020) Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers 12:7, pages 1914.
Crossref
Crossref
Michael J. Peluso, Jessica Chen, Sadie Munter, Asia Reed, Justin Teraoka, Ingrid Eshun-Wilson, Timothy J. Henrich & Peter V. Chin-Hong. (2020) Outcomes of immunomodulatory and biologic therapy in people living with HIV. AIDS 34:8, pages 1171-1179.
Crossref
Crossref
Raúl González, María A. Rodríguez-Hernández, María Negrete, Kalina Ranguelova, Aurelie Rossin, Carmen Choya-Foces, Patricia de la Cruz-Ojeda, Antonio Miranda-Vizuete, Antonio Martínez-Ruiz, Sergio Rius-Pérez, Juan Sastre, José A. Bárcena, Anne-Odile Hueber, C. Alicia Padilla & Jordi Muntané. (2020) Downregulation of thioredoxin-1-dependent CD95 S-nitrosation by Sorafenib reduces liver cancer. Redox Biology 34, pages 101528.
Crossref
Crossref
María A. Rodríguez-Hernández, Patricia de la Cruz-Ojeda, Paloma Gallego, Elena Navarro-Villarán, Pavla Staňková, José A. Del Campo, Otto Kučera, Moustafa Elkalaf, Tumisang E. Maseko, Zuzana Červinková & Jordi Muntané. (2020) Dose-dependent regulation of mitochondrial function and cell death pathway by sorafenib in liver cancer cells. Biochemical Pharmacology 176, pages 113902.
Crossref
Crossref
Shanshan Jiang, Rong Wang, Xuan Zhang, Feihua Wu, Shengnan Li & Yongfang Yuan. (2020) Combination treatment of gemcitabine and sorafenib exerts a synergistic inhibitory effect on non‑small cell lung cancer in�vitro and in�vivo via the epithelial‑to‑mesenchymal transition process. Oncology Letters.
Crossref
Crossref
Mahsa Sedighi, Fereshteh Rahimi, Mohammad-Ali Shahbazi, Ali Hossein Rezayan, Helene Kettiger, Tomaz Einfalt, Jörg Huwyler & Dominik Witzigmann. (2019) Controlled Tyrosine Kinase Inhibitor Delivery to Liver Cancer Cells by Gate-Capped Mesoporous Silica Nanoparticles. ACS Applied Bio Materials 3:1, pages 239-251.
Crossref
Crossref
Kwan-Lung Ko, Lung-Yi Mak, Ka-Shing Cheung & Man-Fung Yuen. (2020) Hepatocellular carcinoma: recent advances and emerging medical therapies. F1000Research 9, pages 620.
Crossref
Crossref
Hoi Ting A. Hau, Oluwaseun Ogundele, Andrew H. Hibbert, Clinton A. L. Monfries, Katherine Exelby, Natalie J. Wood, Jessica Nevarez-Mejia, M. Alejandra Carbajal, Roland A. Fleck, Maria Dermit, Faraz K. Mardakheh, Victoria C. Williams-Ward, Tapan G. Pipalia, Maria R. Conte & Simon M. Hughes. (2020) Maternal Larp6 controls oocyte development, chorion formation and elevation. Development.
Crossref
Crossref
Sreeja Dattachoudhury, Renu Sharma, Atul Kumar & Bithiah Grace Jaganathan. (2020) Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells. Oncology 98:7, pages 478-486.
Crossref
Crossref
Nancy S. Younis, Amal M. H. Ghanim & Sameh Saber. (2019) Mebendazole augments sensitivity to sorafenib by targeting MAPK and BCL-2 signalling in n-nitrosodiethylamine-induced murine hepatocellular carcinoma. Scientific Reports 9:1.
Crossref
Crossref
Muhammad Yasir Ali, Imran Tariq, Muhammad Farhan Sohail, Muhammad Umair Amin, Sajid Ali, Shashank Reddy Pinnapireddy, Asad Ali, Jens Schäfer & Udo Bakowsky. (2019) Selective anti-ErbB3 aptamer modified sorafenib microparticles: In vitro and in vivo toxicity assessment. European Journal of Pharmaceutics and Biopharmaceutics 145, pages 42-53.
Crossref
Crossref
Murat Delman, Sanem Tercan Avcı, İsmail Akçok, Tuğçe Kanbur, Esra Erdal & Ali Çağır. (2019) Antiproliferative activity of (R)-4′-methylklavuzon on hepatocellular carcinoma cells and EpCAM+/CD133+ cancer stem cells via SIRT1 and Exportin-1 (CRM1) inhibition. European Journal of Medicinal Chemistry 180, pages 224-237.
Crossref
Crossref
Mi Na Kim, Seung Min Lee, Jin Sung Kim & Seong Gyu Hwang. (2019) Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology 84:4, pages 809-817.
Crossref
Crossref
Hao Li, Kanghe Xu, Guangzhe Pian & Shu Sun. (2019) Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth. Oncology Letters.
Crossref
Crossref
Maurice Michel, Marcus Hollenbach, Sabine Pohl, Cristina Ripoll & Alexander Zipprich. (2019) Inhibition of Glyoxalase-I Leads to Reduced Proliferation, Migration and Colony Formation, and Enhanced Susceptibility to Sorafenib in Hepatocellular Carcinoma. Frontiers in Oncology 9.
Crossref
Crossref
Kimberley E. Christen, Rohan A. Davis & Derek Kennedy. (2019) Psammaplysin F increases the efficacy of bortezomib and sorafenib through regulation of stress granule formation. The International Journal of Biochemistry & Cell Biology 112, pages 24-38.
Crossref
Crossref
Teresa Faranda, Ilaria Grossi, Michele Manganelli, Eleonora Marchina, Gianluca Baiocchi, Nazario Portolani, Marialuisa Crosatti, Giuseppina De Petro & Alessandro Salvi. (2019) Differential expression profiling of long non-coding RNA GAS5 and miR-126-3p in human cancer cells in response to sorafenib. Scientific Reports 9:1.
Crossref
Crossref
Kehua Zhou & Christos Fountzilas. (2019) Outcomes and Quality of Life of Systemic Therapy in Advanced Hepatocellular Carcinoma. Cancers 11:6, pages 861.
Crossref
Crossref
Raffaele Di Francia, Massimiliano Berretta, Giulio Benincasa, Alfredo D’Avino, Sergio Facchini, Domenico Costagliola & Paola Rossi. (2019) Pharmacogenetic-Based Interactions between Nutraceuticals and Angiogenesis Inhibitors. Cells 8:6, pages 522.
Crossref
Crossref
Avishkar V. Sawant, Shalini Srivastava, Shweta S. Prassanawar, Bhabatarak Bhattacharyya & Dulal Panda. (2019) Crocin, a carotenoid, suppresses spindle microtubule dynamics and activates the mitotic checkpoint by binding to tubulin. Biochemical Pharmacology 163, pages 32-45.
Crossref
Crossref
Hui‐Huang Lai, Chih‐Wei Li, Chih‐Chen Hong, Hung‐Yu Sun, Ching‐Feng Chiu, Da‐Liang Ou & Pai‐Sheng Chen. (2019)
TARBP
2‐mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma
. Molecular Oncology 13:4, pages 928-945.
Crossref
Crossref
Raghupathy Vengoji, Moorthy P Ponnusamy, Satyanarayana Rachagani, Sidharth Mahapatra, Surinder K Batra, Nicole Shonka & Muzafar A Macha. (2019) Novel therapies hijack the blood–brain barrier to eradicate glioblastoma cancer stem cells. Carcinogenesis 40:1, pages 2-14.
Crossref
Crossref
Cristian Turato, Francesca Fornari, Daniela Pollutri, Matteo Fassan, Santina Quarta, Gianmarco Villano, Mariagrazia Ruvoletto, Luigi Bolondi, Laura Gramantieri & Patrizia Pontisso. (2019) MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma. Journal of Clinical Medicine 8:2, pages 171.
Crossref
Crossref
Ahmet Can Timucin, Huveyda Basaga & Ozgur Kutuk. (2019) Selective targeting of antiapoptotic BCL-2 proteins in cancer. Medicinal Research Reviews 39:1, pages 146-175.
Crossref
Crossref
María A. Rodríguez‐Hernández, Raúl González, Ángel J. de la Rosa, Paloma Gallego, Raquel Ordóñez, Elena Navarro‐Villarán, Laura Contreras, Mario Rodríguez‐Arribas, Javier González‐Gallego, José M. Álamo‐Martínez, Luís M. Marín‐Gómez, José A. Del Campo, José L. Quiles, José M. Fuentes, Jesús de la Cruz, José L. Mauriz, Francisco J. Padillo & Jordi Muntané. (2018) Molecular characterization of autophagic and apoptotic signaling induced by sorafenib in liver cancer cells. Journal of Cellular Physiology 234:1, pages 692-708.
Crossref
Crossref
Otília Menyhárt, Ádám Nagy & Balázs Győrffy. (2018) Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma. Royal Society Open Science 5:12, pages 181006.
Crossref
Crossref
Giorgia Marisi, Alessandro Cucchetti, Paola Ulivi, Matteo Canale, Giuseppe Cabibbo, Leonardo Solaini, Francesco G Foschi, Serena De Matteis, Giorgio Ercolani, Martina Valgiusti, Giovanni L Frassineti, Mario Scartozzi & Andrea Casadei Gardini. (2018) Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?. World Journal of Gastroenterology 24:36, pages 4152-4163.
Crossref
Crossref
Wei-De Wu, Pin-Shern Chen, Hany A. Omar, El-Shaimaa A. Arafa, Hung-Wei Pan, Jingyueh Jeng & Jui-Hsiang Hung. (2018) Antrodia cinnamomea boosts the anti-tumor activity of sorafenib in xenograft models of human hepatocellular carcinoma. Scientific Reports 8:1.
Crossref
Crossref
Greeshma Tom, Sheena Philip, Rimal Isaac, P.K. Praseetha, S.G. Jiji & V.V. Asha. (2018) Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma. Life Sciences 206, pages 10-21.
Crossref
Crossref
Abdulmajeed Bahman, Mohamed Abaza, Sarah Khoushiash & Rajaa Al‑Attiyah. (2018) Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action. International Journal of Molecular Medicine.
Crossref
Crossref
Lifang Luo, Lijing Cai, Laibang Luo, Zhimou Tang & Xiaohui Meng. (2018) Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells. Molecular Medicine Reports.
Crossref
Crossref
Maryam Monajati, Shirin Tavakoli, gholam hossein yousefi, Samira Sadat Abolmaali & AliMohammad Tamaddon. (2018) Effect of PEGylation on assembly morphology and cellular uptake of poly ethyleneimine-cholesterol conjugates for delivery of sorafenib tosylate in hepatocellular carcinoma. BioImpacts 8:4, pages 241-252.
Crossref
Crossref
Jelena Krstic, Markus Galhuber, Tim Schulz, Michael Schupp & Andreas Prokesch. (2018) p53 as a Dichotomous Regulator of Liver Disease: The Dose Makes the Medicine. International Journal of Molecular Sciences 19:3, pages 921.
Crossref
Crossref
Oriana Lo Re, Concetta Panebianco, Stefania Porto, Carlo Cervi, Francesca Rappa, Stefano Di Biase, Michele Caraglia, Valerio Pazienza & Manlio Vinciguerra. (2017) Fasting inhibits hepatic stellate cells activation and potentiates anti‐cancer activity of Sorafenib in hepatocellular cancer cells. Journal of Cellular Physiology 233:2, pages 1202-1212.
Crossref
Crossref
Melanie B. Thomas, Elizabeth Garrett-Mayer, Munazza Anis, Kate Anderton, Tricia Bentz, Andie Edwards, Alan Brisendine, Geoffrey Weiss, Abby B. Siegel, Johanna Bendell, Ari Baron, Vinay Duddalwar & Anthony El-Khoueiry. (2018) A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Oncology 94:6, pages 329-339.
Crossref
Crossref
Alessandra Pattarozzi, Elisa Carra, Roberto E. Favoni, Roberto Würth, Daniela Marubbi, Rosa Angela Filiberti, Luciano Mutti, Tullio Florio, Federica Barbieri & Antonio Daga. (2017) The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Stem Cell Research & Therapy 8:1.
Crossref
Crossref
Yanning Liu, Guohua Lou, John T. Norton, Chen Wang, Irawati Kandela, Shuai Tang, Nathaniel I. Shank, Pankaj Gupta, Min Huang, Michael J. Avram, Richard Green, Andrew Mazar, Daniel Appella, Zhi Chen & Sui Huang. (2017) 6‐Methoxyethylamino‐numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. The FASEB Journal 31:12, pages 5453-5465.
Crossref
Crossref
Stephen L. Abrams, Peter P. Ruvolo, Vivian R. Ruvolo, Giovanni Ligresti, Alberto M. Martelli, Lucio Cocco, Stefano Ratti, Agostino Tafuri, Linda S. Steelman, Saverio Candido, Massimo Libra & James A. McCubrey. (2017) Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells. Oncotarget 8:44, pages 76525-76557.
Crossref
Crossref
Hai Zhang, Yina You & Zhongliang Zhu. (2017) The human RNA surveillance factor Up-frameshift 1 inhibits hepatic cancer progression by targeting MRP2/ABCC2. Biomedicine & Pharmacotherapy 92, pages 365-372.
Crossref
Crossref
Chang Woo Han, Mi Suk Jeong & Se Bok Jang. (2017) Structure, signaling and the drug discovery of the Ras oncogene protein. BMB Reports 50:7, pages 355-360.
Crossref
Crossref
Edoardo Abeni, Alessandro Salvi, Eleonora Marchina, Michele Traversa, Bruna Arici & Giuseppina De Petro. (2017) Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells. International Journal of Oncology 51:1, pages 128-144.
Crossref
Crossref
Savita Mishra & Deepshikha Pande Katare. (2017)
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An
In Silico
and
In Vitro
Approach
. Basic & Clinical Pharmacology & Toxicology 120:6, pages 532-540.
Crossref
Crossref
Shanshan Jiang, Qian Wang, Meiqing Feng, Jiyang Li, Zhongbin Guan, Duopeng An, Mengxue Dong, Yuzhe Peng, Kudelaidi Kuerban & Li Ye. (2016) C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells. Applied Microbiology and Biotechnology 101:4, pages 1535-1546.
Crossref
Crossref
Weitong Sun, Yong Wang, Mingyue Cai, Liteng Lin, Xiaoyan Chen, Zhong Cao, Kangshun Zhu & Xintao Shuai. (2017) Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy. Biomaterials Science 5:12, pages 2468-2479.
Crossref
Crossref
Giuseppe Tridente. 2017. Adverse Events and Oncotargeted Kinase Inhibitors. Adverse Events and Oncotargeted Kinase Inhibitors
167
197
.
Massimiliano Berretta, Luca Rinaldi, Fabrizio Di Benedetto, Arben Lleshi, Vallì De Re, Gaetano Facchini, Paolo De Paoli & Raffaele Di Francia. (2016) Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma. Frontiers in Pharmacology 7.
Crossref
Crossref
Mohieldin M. Youssef , Mai F. Tolba, Noha N. Badawy, Andrew W. Liu, Eman El-Ahwany, Amani E. Khalifa, Suher Zada & Ashraf B. Abdel-Naim. (2016) Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells. Scientific Reports 6:1.
Crossref
Crossref
Germán F. Giri, Mauro Danielli, Raúl A. Marinelli & Rolando A. Spanevello. (2016) Cytotoxic effect of levoglucosenone and related derivatives against human hepatocarcinoma cell lines. Bioorganic & Medicinal Chemistry Letters 26:16, pages 3955-3957.
Crossref
Crossref
M R Emma, J L Iovanna, D Bachvarov, R Puleio, G R Loria, G Augello, S Candido, M Libra, A Gulino, V Cancila, J A McCubrey, G Montalto & M Cervello. (2016) NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance. Cell Death & Disease 7:6, pages e2269-e2269.
Crossref
Crossref
Nestor Prieto-Domínguez, Raquel Ordóñez, Anna Fernández, Andres García-Palomo, Jordi Muntané, Javier González-Gallego & José L. Mauriz. (2016) Modulation of Autophagy by Sorafenib: Effects on Treatment Response. Frontiers in Pharmacology 7.
Crossref
Crossref
Chiun Hsu, Liang-In Lin, Yu-Che Cheng, Zi-Rui Feng, Yu-Yun Shao, Ann-Lii Cheng & Da-Liang Ou. (2016) Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Clinical Cancer Research 22:10, pages 2555-2564.
Crossref
Crossref
Wei Chen, Weikai Xiao, Kunsong Zhang, Xiaoyu Yin, Jiaming Lai, Lijian Liang & Dong Chen. (2016) Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence. Scientific Reports 6:1.
Crossref
Crossref
Jia-Nian Chen, Xian-Fu Wang, Ting Li, De-Wen Wu, Xiao-Bo Fu, Guang-Ji Zhang, Xing-Can Shen & Heng-Shan Wang. (2016) Design, synthesis, and biological evaluation of novel quinazolinyl-diaryl urea derivatives as potential anticancer agents. European Journal of Medicinal Chemistry 107, pages 12-25.
Crossref
Crossref
Maria Luisa Bondì, Chiara Botto, Erika Amore, Maria Rita Emma, Giuseppa Augello, Emanuela Fabiola Craparo & Melchiorre Cervello. (2015) Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells. International Journal of Pharmaceutics 493:1-2, pages 75-85.
Crossref
Crossref
Francesca V. Negri, Barbara Dal Bello, Camillo Porta, Nicoletta Campanini, Sandro Rossi, Carmine Tinelli, Guido Poggi, Gabriele Missale, Silvia Fanello, Stefania Salvagni, Andrea Ardizzoni & Silini Enrico Maria. (2015) Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment. Liver International 35:8, pages 2001-2008.
Crossref
Crossref
Agostina Grillone, Eugenio Redolfi Riva, Alessio Mondini, Claudia Forte, Lucia Calucci, Claudia Innocenti, Cesar de Julian Fernandez, Valentina Cappello, Mauro Gemmi, Stefania Moscato, Francesca Ronca, Rodolfo Sacco, Virgilio Mattoli & Gianni Ciofani. (2015) Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles. Advanced Healthcare Materials 4:11, pages 1681-1690.
Crossref
Crossref
Bo Zhai, Xian Jiang, Changjun He, Dali Zhao, Lixin Ma, Lishan Xu, Hongchi Jiang & Xueying Sun. (2014) Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumor Biology 36:4, pages 2323-2334.
Crossref
Crossref
Giovan Giuseppe Di Costanzo, Giorgio de Stefano, Raffaella Tortora, Nunzia Farella, Luigi Addario, Filippo Lampasi, Alfonso Galeota Lanza, Gabriella Cordone, Michele Imparato & Nicola Caporaso. (2015) Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 11:6, pages 943-951.
Crossref
Crossref
Jian Kong, Fandong Kong, Jun Gao, Qiangbo Zhang, Shuying Dong, Fang Gu, Shan Ke, Bing Pan, Qiang Shen, Huichuan Sun, Lemin Zheng & Wenbing Sun. (2014) YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma. Molecular Cancer 13:1.
Crossref
Crossref
A-Young Choi, Ji Hyun Choi, Keun-Young Hwang, Yeon Ju Jeong, Wonchae Choe, Kyung-Sik Yoon, Joohun Ha, Sung Soo Kim, Jang Hyun Youn, Eui-Ju Yeo & Insug Kang. (2013) RETRACTED ARTICLE: Licochalcone A induces apoptosis through endoplasmic reticulum stress via a phospholipase Cγ1-, Ca2+-, and reactive oxygen species-dependent pathway in HepG2 human hepatocellular carcinoma cells. Apoptosis 19:4, pages 682-697.
Crossref
Crossref
Francesca Capone, Eliana Guerriero, Angela Sorice, Giovanni Colonna, Gabriella Storti, Jessica Pagliuca, Giuseppe Castello & Susan Costantini. (2014) Synergistic Antitumor Effect of Doxorubicin and Tacrolimus (FK506) on Hepatocellular Carcinoma Cell Lines. The Scientific World Journal 2014, pages 1-9.
Crossref
Crossref
Roberto Würth, Federica Barbieri & Tullio Florio. (2014) New Molecules and Old Drugs as Emerging Approaches to Selectively Target Human Glioblastoma Cancer Stem Cells. BioMed Research International 2014, pages 1-11.
Crossref
Crossref
Alessandro Salvi, Isabel Conde, Edoardo Abeni, Bruna Arici, Ilaria Grossi, Claudia Specchia, Nazario Portolani, Sergio Barlati & Giuseppina De Petro. (2013) Effects of miR-193a and sorafenib on hepatocellular carcinoma cells. Molecular Cancer 12:1.
Crossref
Crossref
Rosalba D’Alessandro, Maria G. Refolo, Catia Lippolis, Caterina Messa, Aldo Cavallini, Roberta Rossi, Leonardo Resta, Antonio Di Carlo & Brian I. Carr. (2013) Reversibility of regorafenib effects in hepatocellular carcinoma cells. Cancer Chemotherapy and Pharmacology 72:4, pages 869-877.
Crossref
Crossref
Carolina Simioni, Alberto M. Martelli, Alice Cani, Rengul Cetin-Atalay, James A. McCubrey, Silvano Capitani & Luca M. Neri. (2013) The AKT Inhibitor MK-2206 is Cytotoxic in Hepatocarcinoma Cells Displaying Hyperphosphorylated AKT-1 and Synergizes with Conventional Chemotherapy. Oncotarget 4:9, pages 1496-1506.
Crossref
Crossref
Claudia Fumarola, Cristina Caffarra, Silvia La Monica, Maricla Galetti, Roberta R. Alfieri, Andrea Cavazzoni, Elena Galvani, Daniele Generali, Pier Giorgio Petronini & Mara A. Bonelli. (2013) Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK–mTORC1 signaling. Breast Cancer Research and Treatment 141:1, pages 67-78.
Crossref
Crossref
Melchiorre Cervello, Dimcho Bachvarov, Nadia Lampiasi, Antonella Cusimano, Antonina Azzolina, James A. McCubrey & Giuseppe Montalto. (2013) Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells. PLoS ONE 8:6, pages e65569.
Crossref
Crossref
Youn Kyoung Jeong, Mi-Sook Kim, Ji Young Lee, Eun Ho Kim, Wonwoo Kim, Hunjoo Ha & Jae-Hoon Jeong. (2018) Sorafenib Acts Synergistically in Combination with Radiotherapy without Causing Intestinal Damage in Colorectal Cancer. Tumori Journal 99:2, pages 176-182.
Crossref
Crossref
James A. McCubrey, Linda S. Steelman, William H. Chappell, Lin Sun, Nicole M. Davis, Stephen L. Abrams, Richard A. Franklin, Lucio Cocco, Camilla Evangelisti, Francesca Chiarini, Alberto M. Martelli, Massimo Libra, Saverio Candido, Giovanni Ligresti, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Marco Donia, Ferdinando Nicoletti, Jerry Polesel, Renato Talamini, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Joanna Dulińska-Litewka, Piotr Laidler, Antonio B. D’Assoro, Lyudmyla Drobot, Kazuo Umezawa, Giuseppe Montalto, Melchiorre Cervello & Zoya N. Demidenko. (2012) Advances in Targeting Signal Transduction Pathways. Oncotarget 3:12, pages 1505-1521.
Crossref
Crossref
James A. McCubrey, Linda S. Steelman, William H. Chappell, Stephen L. Abrams, Richard A. Franklin, Giuseppe Montalto, Melchiorre Cervello, Massimo Libra, Saverio Candido, Grazia Malaponte, Maria C. Mazzarino, Paolo Fagone, Ferdinando Nicoletti, Jörg Bäsecke, Sanja Mijatovic, Danijela Maksimovic-Ivanic, Michele Milella, Agostino Tafuri, Francesca Chiarini, Camilla Evangelisti, Lucio Cocco & Alberto M. Martelli. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. Oncotarget 3:10, pages 1068-1111.
Crossref
Crossref